FDA Opens RFI on AI-Enabled Optimization of Early-Phase Clinical Trials
The U.S. Food and Drug Administration has published a Request for Information seeking industry input on the use of AI to optimize early-phase clinical trial design and execution. The RFI is part of a federal pilot program exploring whether AI can compress drug development timelines while maintaining safety and efficacy standards.
For enterprise AI and life sciences leaders, the RFI is an early regulatory signal of U.S. appetite for AI-assisted trial design. Input received will inform how the FDA shapes oversight frameworks governing AI use in clinical settings — a foundational policy question for any company building AI products for pharmaceutical or biotech customers.